Codartium

✦ For everyone, free.

Practical knowledge for real-world learning, work, problem solving, and everyday life

Home

1. Obesity Assessment

Learn how obesity assessment works through BMI evaluation, body composition analysis, and nutritional studies..

Obesity assessment is the structured, multidimensional clinical process of evaluating excess body fat accumulation, its anatomical distribution, its degree of severity, its underlying determinants, and its health consequences in an individual patient. It goes far beyond the recording of body weight — it integrates anthropometric measurement, metabolic and biochemical investigation, clinical examination, functional evaluation, and psychosocial appraisal to produce a comprehensive understanding of the patient's obesity phenotype and to guide individualized, evidence-based treatment planning. Obesity is recognized by the World Health Organization, the American Medical Association, and major endocrinological societies as a chronic, relapsing, multifactorial disease that requires the same systematic assessment applied to any other complex medical condition.

Why Comprehensive Obesity Assessment Matters

Body weight alone is an insufficient basis for clinical decision-making in obesity. Two individuals with identical BMI values may have profoundly different metabolic risk profiles, fat distribution patterns, functional capacities, aetiological drivers, and treatment needs. Comprehensive assessment identifies which patients require urgent metabolic intervention, which obesity-related comorbidities are already present, what the primary drivers of weight gain are (so they can be addressed), what barriers to treatment exist, and which therapeutic modalities — lifestyle, pharmacological, or surgical — are appropriate.

Five Domains of Comprehensive Obesity Assessment Anthropo- metric BMI · Waist Body comp. Metabolic Labs · Glucose Lipids · BP Clinical Exam · Signs Comorbidities Aetiological Causes · Diet Meds · Sleep Psycho- social Mental health Quality of life Assessment findings from all five domains inform a unified treatment plan

Anthropometric Assessment

Anthropometric measurement provides the quantitative foundation of obesity assessment, capturing the extent of excess fat mass and its distribution pattern.

Body Mass Index

BMI is the standard entry-level classification tool, calculated as weight (kg) divided by height (m) squared. It is used to categorize obesity into severity classes.

WHO Obesity Classification by BMI Category BMI (kg/m²) Risk Level Normal weight 18.5 – 24.9 Average Overweight (Pre-obese) 25.0 – 29.9 Increased Obesity — Class I 30.0 – 34.9 Moderate Obesity — Class II 35.0 – 39.9 Severe Obesity — Class III (Morbid) ≥ 40.0 Very Severe

While BMI provides an essential starting classification, its limitations in obesity assessment are significant. It does not distinguish fat mass from lean mass, does not reflect fat distribution, and uses thresholds derived predominantly from European populations. Modified thresholds (overweight ≥23, obesity ≥27.5) apply to East and South Asian populations.

Waist Circumference

Waist circumference is measured at the midpoint between the lower costal margin and the iliac crest, taken at the end of a normal expiration. It is the primary clinical proxy for visceral adiposity — the metabolically active, cardiovascular risk-driving fat depot surrounding the abdominal organs.

Waist Circumference Risk Thresholds Population Increased Risk High Risk European — Men ≥ 94 cm ≥ 102 cm European — Women ≥ 80 cm ≥ 88 cm Asian (Men/Women) ≥ 90 / ≥ 80 cm Lower thresholds apply

Waist circumference adds independent predictive value to BMI. An individual with a normal BMI but elevated waist circumference — termed metabolically obese normal weight (MONW) or central obesity — carries substantially greater cardiometabolic risk than their BMI alone would suggest.

Waist-to-Height Ratio

Waist-to-height ratio (WHtR = waist circumference cm ÷ height cm) is increasingly recognized as a superior predictor of cardiometabolic risk compared to BMI or waist circumference alone. A WHtR above 0.50 is proposed as a universal action threshold — the waist should be less than half the height. Its advantage is that it self-adjusts for stature, eliminating the systematic underestimation of central adiposity risk in taller individuals.

Waist-to-Hip Ratio

Waist-to-hip ratio (WHR) distinguishes android (apple-shaped) from gynoid (pear-shaped) fat distribution, with android pattern conferring higher cardiovascular and metabolic risk. WHO risk thresholds are WHR >0.90 for men and >0.85 for women.

Body Composition Analysis

When available, formal body composition analysis provides direct quantification of fat mass and fat-free mass, moving beyond the proxy measures of BMI and circumferences. Methods used in obesity assessment include:

  • DXA (Dual-energy X-ray absorptiometry): three-compartment analysis providing regional fat distribution data and assessment of sarcopenic obesity (excess fat combined with depleted lean mass).
  • Bioelectrical impedance analysis (BIA): accessible, non-invasive estimation of body composition from electrical resistance; sensitive to hydration status.
  • CT and MRI: gold standard for quantifying visceral adipose tissue (VAT) volume directly, used primarily in research settings.

The Edmonton Obesity Staging System

The Edmonton Obesity Staging System (EOSS) is a five-stage clinical severity classification system that stratifies patients based on the presence and severity of obesity-related comorbidities and functional impairment, rather than BMI alone. It is the most clinically useful classification framework for treatment prioritization because it directly reflects health impact.

Edmonton Obesity Staging System (EOSS) Stage Clinical Status Stage 0 No apparent risk factors, symptoms, or comorbidities Stage 1 Subclinical risk factors present (pre-diabetes, hypertension) Stage 2 Established comorbidities with mild-moderate functional impairment Stage 3 Severe end-organ damage and significant functional limitation Stage 4 Severe comorbidities, disability, and potentially end-of-life issues

EOSS stage — not BMI class alone — should determine treatment intensity. A Stage 2 patient at BMI 32 requires more aggressive intervention than a Stage 0 patient at BMI 38. This framework is now embedded in major obesity management guidelines.

Metabolic and Biochemical Assessment

Biochemical investigation identifies the cardiometabolic consequences of obesity that are not externally visible and that constitute the primary drivers of morbidity and mortality.

Core Biochemical Investigations in Obesity Glycaemic Status Fasting plasma glucose HbA1c (glycated haemoglobin) Fasting insulin (HOMA-IR) Oral glucose tolerance test if fasting glucose borderline Lipid and Cardiovascular Fasting lipid panel (TC, LDL, HDL) Triglycerides Blood pressure (both arms) hsCRP (systemic inflammation) ECG if cardiac history
Hepatic Liver enzymes (ALT, AST) GGT · Bilirubin → NAFLD screening Endocrine TSH (thyroid function) Cortisol (Cushing's screen) Testosterone (men) Renal and Nutritional eGFR · Creatinine Uric acid (gout risk) Vitamin D · Ferritin · B12

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is calculated as fasting insulin (µIU/mL) × fasting glucose (mmol/L) ÷ 22.5. Values above 2.5 indicate clinically significant insulin resistance, a key driver of type 2 diabetes, hypertension, and dyslipidaemia in obese patients.

HbA1c reflects average blood glucose over the preceding 2–3 months. Values of 39–47 mmol/mol (5.7–6.4%) define pre-diabetes; ≥48 mmol/mol (≥6.5%) defines type 2 diabetes.

Metabolic Syndrome Assessment

Metabolic syndrome is a clustering of cardiometabolic risk factors that occurs with high prevalence in obesity and dramatically amplifies cardiovascular and type 2 diabetes risk. Diagnosis requires three or more of five criteria.

Metabolic Syndrome — Diagnostic Criteria (IDF/AHA) Diagnosis requires ≥ 3 of the following 5 criteria ① Central obesity: Waist ≥94 cm (men) / ≥80 cm (women) — European thresholds ② Fasting glucose: ≥ 5.6 mmol/L (100 mg/dL) or on glucose-lowering therapy ③ Blood pressure: Systolic ≥130 or diastolic ≥85 mmHg, or on antihypertensive therapy ④ Triglycerides: ≥ 1.7 mmol/L (150 mg/dL) or on triglyceride-lowering therapy ⑤ HDL cholesterol: <1.0 mmol/L (men) / <1.3 mmol/L (women), or on HDL therapy

Clinical Examination in Obesity Assessment

The clinical examination in obesity assessment extends beyond the standard physical examination to detect obesity-related comorbidities and signs that may reveal the aetiology of weight gain.

Cardiovascular and Respiratory Examination

Blood pressure must be measured with an appropriately sized cuff — using a standard adult cuff on a large arm artificially elevates the reading. Resting ECG identifies left ventricular hypertrophy, arrhythmias, and ischaemic changes. Auscultation assesses for heart failure (S3 gallop, bibasal crackles), pulmonary hypertension (loud P2), and sleep apnoea sequelae.

Signs of Obesity-Related Endocrine Disorders

Physical signs guide the identification of secondary causes of obesity that require specific treatment.

Clinical Signs Suggesting Secondary Obesity Causes Cushing's Syndrome Central adiposity · moon face Buffalo hump · purple striae Proximal muscle weakness Easy bruising · thin skin Hypothyroidism Weight gain · fatigue Cold intolerance · dry skin Bradycardia · constipation Periorbital oedema · goitre Both conditions require targeted treatment before obesity management is optimized

Additional examination findings relevant to obesity include acanthosis nigricans (hyperpigmented, velvety skin in the neck folds and axillae, indicating insulin resistance), hirsutism and oligomenorrhoea (suggesting polycystic ovary syndrome in women), hepatomegaly (non-alcoholic fatty liver disease), and pretibial oedema (venous insufficiency, heart failure, or lymphoedema).

Obesity-Related Comorbidity Screening

A structured comorbidity review is integral to obesity assessment, as obesity simultaneously affects virtually every organ system. Identified comorbidities determine treatment urgency, influence treatment selection, and are primary targets of obesity management.

Obesity-Related Comorbidities by System Cardiovascular Hypertension CAD / Heart failure AF · DVT · PE Stroke Metabolic Type 2 diabetes NAFLD / NASH Dyslipidaemia PCOS · Gout Other Systems Obstructive sleep apnoea OA · Low back pain GORD · Incontinence Cancer (multiple types) Depression · Anxiety Systematic comorbidity screening identifies conditions requiring co-management

Obstructive sleep apnoea (OSA) deserves particular emphasis: it is present in approximately 40–70% of patients with obesity and is frequently undiagnosed. The STOP-BANG questionnaire (Snoring, Tiredness, Observed apnoea, blood Pressure, BMI >35, Age >50, Neck >40 cm, male Gender) screens for OSA risk, with a score ≥3 indicating high risk requiring polysomnography referral.

Aetiological Assessment

Identifying the drivers of weight gain is essential for effective, personalized treatment. Obesity develops from a complex interaction of genetic, environmental, behavioural, pharmacological, and endocrine factors.

Dietary and Physical Activity Assessment

Dietary intake is assessed through 24-hour dietary recall, multiple-day food diaries, or validated food frequency questionnaires. Key areas of enquiry include total energy intake, eating patterns (meal frequency, portion size, speed of eating), ultra-processed food consumption, emotional and binge eating behaviors, and fluid caloric intake (sweetened beverages, alcohol).

Physical activity assessment uses validated tools including the International Physical Activity Questionnaire (IPAQ) or accelerometry. Sedentary behavior — particularly prolonged sitting — is assessed independently from exercise, as it carries independent cardiometabolic risk.

Weight History

The weight history establishes the trajectory and context of weight gain: highest and lowest adult weight, age of onset of obesity, triggering life events (pregnancy, medication changes, bereavement, career change), rate of weight gain, previous weight loss attempts (methods used, magnitude of loss, duration, reasons for regain), and the patient's own explanatory model of their weight.

Medication Review

Multiple commonly prescribed medications cause clinically significant weight gain, which must be identified and substituted where clinically feasible before assuming behavioral causes predominate.

Common Medications Associated with Weight Gain Psychiatric Olanzapine · Quetiapine Lithium · Valproate Endocrine Insulin · Sulfonylureas Glucocorticoids Other Classes Beta-blockers · Antihistamines Antidepressants (TCAs, MAOIs) Medication review can identify reversible contributors to weight gain

Psychosocial and Mental Health Assessment

The bidirectional relationship between obesity and mental health is strong and clinically important. Depression and anxiety are both risk factors for weight gain (through emotional eating, reduced activity, and the metabolic effects of dysregulated cortisol and sleep) and consequences of obesity (through stigma, functional impairment, and reduced quality of life).

Depression is screened using the PHQ-9 (Patient Health Questionnaire), with scores ≥10 indicating moderate depression. Anxiety is screened with the GAD-7 (Generalized Anxiety Disorder scale). Both instruments are brief, validated, and routinely integrated into obesity assessment.

Binge eating disorder (BED) — defined by recurrent episodes of consuming large amounts of food rapidly with loss of control and marked distress, without compensatory purging — affects approximately 5–30% of patients presenting for obesity treatment. It is screened using the Binge Eating Scale (BES) or the SCOFF questionnaire. BED requires psychological treatment as the primary intervention; weight management strategies applied without addressing BED are ineffective and potentially harmful.

Health-related quality of life is assessed using validated tools including the Obesity-Related Well-Being Questionnaire (ORWELL-97), the Impact of Weight on Quality of Life-Lite (IWQOL-Lite), or the generic Short Form-36 (SF-36), capturing the physical, social, and emotional domains of functioning affected by obesity.

Weight stigma and bias — both internalized and experienced from external sources including healthcare providers — are associated with psychological harm, avoidance of healthcare, disordered eating, and poorer treatment outcomes. Assessment includes enquiry about previous negative experiences in healthcare settings, workplace discrimination, and the patient's own attitudes toward their body and weight.

Functional and Physical Assessment

Obesity impairs physical function through mechanical loading of joints, reduced cardiorespiratory reserve, and the systemic effects of metabolic inflammation. Functional assessment identifies limitations that affect quality of life, treatment capacity, and surgical eligibility.

Physical performance is evaluated using the 6-minute walk test (6MWT), timed up-and-go (TUG) test, and handgrip dynamometry. The 6MWT assesses cardiorespiratory exercise tolerance; the TUG assesses mobility and fall risk; grip strength is a validated proxy for total body muscle strength and a predictor of surgical outcomes.

Musculoskeletal assessment identifies osteoarthritis (particularly knee and hip), chronic low back pain, and plantar fasciitis — all of which are both caused and exacerbated by obesity and may limit exercise capacity during treatment.

Respiratory function includes spirometry (screening for obesity hypoventilation syndrome and asthma), peak expiratory flow rate, and, where indicated, sleep study referral for OSA assessment.

Cardiovascular Risk Stratification

Formal cardiovascular risk stratification integrates the findings of obesity assessment into a composite risk estimate that guides treatment intensity and medical co-management targets. The Framingham Risk Score, QRISK3 (in UK practice), and the ACC/AHA Pooled Cohort Equations estimate 10-year cardiovascular event risk from age, sex, smoking status, systolic BP, total and HDL cholesterol, and diabetes status. High cardiovascular risk (10-year risk >20%) in an obese patient identifies a population requiring simultaneous aggressive obesity treatment and intensive cardiovascular risk factor management.

Assessment for Bariatric Surgery Eligibility

For patients with Class III obesity (BMI ≥40) or Class II obesity (BMI 35–39.9) with significant comorbidities, bariatric surgery assessment constitutes a specialized component of obesity assessment. Standard eligibility criteria include BMI thresholds, documented failure of non-surgical treatment, absence of active psychosis or substance misuse, psychological fitness for surgery, and commitment to post-surgical dietary and lifestyle requirements.

Pre-surgical assessment includes upper gastrointestinal endoscopy (to exclude pathology), cardiac and pulmonary risk stratification, nutritional status assessment (identifying deficiencies requiring pre-correction), full psychological evaluation, and multidisciplinary team review. Post-surgical life-long nutritional supplementation and monitoring requirements are established during this assessment phase.

Synthesizing the Obesity Assessment

A comprehensive obesity assessment concludes with the synthesis of all domains into a unified clinical formulation that addresses four questions: how severe is this patient's obesity and its health impact (classification and staging), what is driving it (aetiology), what are its current health consequences (comorbidities), and what are this patient's barriers and enablers to treatment (psychosocial and functional factors)? This formulation directly generates the individualized, multimodal treatment plan — encompassing dietary intervention, physical activity prescription, behavioral and psychological support, pharmacotherapy, and consideration of surgical options — that is the ultimate purpose of the assessment process.

Content in this section